01 May 2011: Hypothesis
SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease
Yasar Colak ABDEFG , Oguzhan Ozturk DEF , Ebubekir Senates DEF , Ilyas Tuncer ADE , Elif Yorulmaz F , Gupse Adali F , Levent Doganay B , Feruze Yilmaz Enc A
DOI: 10.12659/MSM.881749
Med Sci Monit 2011; 17(5): HY5-9
Abstract
ABSTRACT: Sirtuins are members of the silent information regulator 2 (Sir2) family, a group of Class III histone/protein deacetylases. There are 7 different sirtuins in mammals (SIRT1-7), of which SIRT1 is the best known and most studied. SIRT1 is responsible for the regulation of protein activation by means of deacetylating a variety of proteins that play important roles in the pathophysiology of metabolic diseases. Recently, it has been shown that SIRT1 plays key roles in the regulation of lipid and glucose homeostasis, control of insulin secretion and sensitivity, antiinflammatory effects, control of oxidative stress and the improvements in endothelial function that result due to increased mitochondrial biogenesis and β-oxidation capacity. Nonalcoholic fatty liver disease (NAFLD) is currently the most common liver disease, and it has been accepted as the hepatic component of metabolic syndrome. Recent studies have shown that SIRT expression in the liver is significantly decreased in an NAFLD model of rats fed a high-fat diet, and moderate SIRT1 overexpression protects mice from developing NAFLD. In addition to resveratrol, a natural SIRT1 activator, small-molecule pharmacologic SIRT1 activators have positive effects on metabolic diseases. These effects are particularly promising in the case of diabetes mellitus, for which phase studies are currently being performed. With this information, we hypothesized that the pharmacologic activation of SIRT1, which has been implicated in the pathogenesis of NAFLD, will be a potential therapeutic target for treating NAFLD. In this paper, we review the metabolic effects of SIRT1 and its association with the pathophysiology of NAFLD.
Keywords: Liver - metabolism, Lipid Metabolism - drug effects, Insulin - secretion, Fatty Liver - therapy, Enzyme Activators - pharmacology, Sirtuin 1 - metabolism
Background
Nonalcoholic fatty liver disease (NAFLD) is among the most common causes of chronic liver disease worldwide [1]. The prevalence of NAFLD in the general population of Western countries is 20–30% [2]. Within the spectrum of NAFLD, only nonalcoholic steatohepatitis (NASH) has been convincingly shown to have a progressive course. Approximately 2–3% of the general population is estimated to have NASH [2]. NASH may lead to cirrhosis, hepatocellular carcinoma or liver failure. Most patients with NAFLD have risk factors such as insulin resistance, obesity or other indications of metabolic syndrome. Therefore, NAFLD is now recognized as the hepatic manifestation of metabolic syndrome.
Insulin resistance, oxidative stress, and inflammatory cascades are believed to play integral roles in the pathogenesis and progression of NAFLD [3]. As such, a “multi-hit” (formerly “double-hit”) hypothesis has been used to describe the pathogenesis of NAFLD [4,5]. As a result of the first “hit,” insulin resistance arises and increased fatty acid levels in the blood enter the liver (and/or are not removed from the liver), thus leading to hepatosteatosis. The second “hit” occurs as a result of the inflammation caused by the hepatosteatosis. The criterion standard method for the diagnosis of NAFLD, which most frequently presents with an asymptomatic increase of transaminase enzymes, is a liver biopsy [6].
Despite evidence that weight loss, dietary modifications, bariatric surgical operations, exercise and several drugs result in the biochemical and histological resolution of NAFLD, there is no current treatment regimen supported by valid, long-term studies that were properly randomized and controlled [7–10]. Currently, the basis for treatment includes managing risk factors such as hyperlipidemia through steps such as lifestyle modification and weight loss.
SIRT1 is an NAD+-dependent deacetylase and acts as a modulator of various metabolic pathways. In this article, we focus on the sirtuin 1 (SIRT1) protein, which has important effects on glucose homeostasis, lipid mobilization, β-oxidation, oxidative stress, insulin secretion and sensitivity, inflammation, cellular aging and apoptosis. We discuss the expression of SIRT1 in cases of NAFLD, the results of SIRT1 activation and the potential therapeutic role for SIRT1 in treating NAFLD.
Overview of SIRT1 and SIRT1 Activators
Silent information regulator 2 (Sir2) proteins, or sirtuins, are a class of proteins that possess either histone deacetylase or mono-ADP-ribosyl transferase activity. They are found in organisms ranging from bacteria to humans. SIRT1, an NAD+-dependent protein deacetylase, is an important regulator of energy homeostasis in response to nutrient availability. Currently, the best-studied sirtuin homolog, SIRT1, is expressed in metabolic tissues such as liver, skeletal muscle, adipose tissue, pancreas and brain; its actions in these tissues include regulation of β-cell and neuron survival, hepatic gluconeogenesis, insulin secretion and adiposity [11].
Resveratrol (
1. Effects of SIRT1 in the Liver
The liver is the central metabolic organ and regulates several key aspects of lipid metabolism (fatty acid β-oxidation, lipogenesis and lipoprotein uptake and secretion) in response to nutritional and hormonal signals [18].
Nutritional intake in excess of the β-oxidation capacity of the cell, lipoprotein synthesis and defects in excretion form the foundation of hepatosteatosis. Over time, the transcriptional network of the liver contributes to an inflammatory process that progressively leads to NASH associated with fibrosis, liver cirrhosis, hepatocellular carcinoma and death due to liver disease [19].
In several recent studies, SIRT1 has been shown to play an important role in the dynamics of NAFLD pathophysiology. Using an experimental NAFLD model consisting of rats fed a high-calorie diet, SIRT1 expression was found to decrease significantly. Another study in rats with NAFLD showed a significant increase in hepatic SIRT1 expression and histological improvement with calorie limitation [20,21].
In a study by Purushotham et al. [22], hepatocyte-specific loss of SIRT1 (through hepatocyte-specific deletion of SIRT1) was shown to cause peroxisome proliferator-activated receptor α (PPARα) signal failure and a decrease in fatty acid β-oxidation. However, SIRT1 overexpression increased levels of PPARα and its coactivator PPARγ coactivator 1α (PGC-1α). PGC-1α impairs PPARα signaling and decreases fatty acid β-oxidation, whereas overexpression of SIRT1 induces the expression of PPARα’s targets. SIRT1 interacts with PPARα and is required to activate the PPARγ coactivator PGC-1α. In a recently reported study in rats, SIRT1 was shown to confer protection against age-associated metabolic damage, lead to healthier aging, decrease the frequency of liver cancer related to metabolic syndrome and protect the liver from carcinogenic damage [23].
Studies performed at the molecular level have demonstrated that SIRT1 plays an important role in the regulation of the transcriptional networks controlling various critical metabolic processes in the liver [24–26]. Along those lines, SIRT1 has been shown to deacetylate many nonhistone proteins, including p53, nuclear factor kappa B (NF-κB), forkhead box class O 3 (FOXO3) transcription factors, PGC-1α, liver X-receptor (LXR), CLOCK, PER2 and TORC2 [27–36].
In a study by Yamazaki et al. [37], treatment of mice modeling NAFLD with a SIRT1 activator (SRT1720) resulted in decreases in expression of lipogenic genes (such as those encoding sterol regulatory element-binding protein-1c [SREBP-1c], acyl-CoA carboxylase [ACC] and fatty acid synthase [FAS]), serum lipid profile, fat accumulation in the liver, expression of genes related to oxidative stress and the production of inflammatory cytokines.
In a study of bariatric surgical cases performed by Costa et al. [38], morbidly obese patients with severe hepatosteatosis were determined to have reduced expression of SIRT1 in adipose tissue when compared to patients with mild hepatosteatosis.
2. Effects of SIRT1 on Insulin Secretion
Insulin resistance forms the primary mechanism underlying the pathogenesis of NAFLD. Recent studies have shown that SIRT1 plays important roles in both insulin resistance and insulin regulation in diabetics (such as increasing insulin secretion from pancreatic β-cells, stimulating lipolysis in adipose tissue and increasing glucose utilization in muscle tissue) [31,32,36].
In pancreatic β-cells, SIRT1 has been shown to increase insulin secretion through the repression of uncoupling protein 2 (UCP2) [39]. It was also demonstrated that SIRT1 activation increases ATP production in β-cells and improves glucose-dependent insulin secretion, which typically decreases with age [39,40]. A recent study demonstrated that inhibiting SIRT1 overexpression and NF-κB signaling decreases cytokine-induced pancreatic β-cell damage [41].
As a result, SIRT1 activation prevents the development of insulin resistance and limits the pancreatic β-cell dysfunction that develops in response to insulin resistance.
3. Effects of SIRT1 on Lipid Metabolism
The liver also plays an important role in lipid homeostasis. It has been shown that SIRT1 activation increases lipolysis by repressing PPARγ in adipose tissue, thereby inhibiting adipogenesis [42]. SIRT1 also regulates the production and/or secretion of insulin-sensitizing factors such as adiponectin and FGF21 through the regulation of FOXO1 and PPARγ [43–45].
LXRs regulate the transfer of cholesterol from peripheral tissues to the liver (reverse cholesterol transport) [46,47]. SIRT1 activates LXRs and accelerates reverse cholesterol transport, thereby regulating cholesterol homeostasis [33].
4. Effects of SIRT1 in Skeletal Muscle
SIRT1 is an important regulator of energy metabolism in skeletal muscle. PGC-1α deacetylation by SIRT1 in skeletal muscle is necessary for the activation of mitochondrial fatty acid oxidation genes [48]. As further evidence of the important of SIRT1 in muscle, patients with type 2 diabetes show reduced expression of PGC-1α and mitochondrial
5. Other Effects of SIRT1
Recent studies have begun to address the relationship between sirtuins and age-related metabolic and cardiovascular diseases, antiinflammatory properties, anticarcinogenic effects, effects on oxidative stress and the cell cycle and anti-aging effects.
Epidemiological evidence gathered from NAFLD patients demonstrates that both cardiovascular disease risk and mortality are significantly increased when compared to a normal population [53–55]. Recent studies have shown the cardioprotective potential of SIRT1 activation. The cause of these effects may include vascular relaxation (both by increasing endothelial nitric oxide synthase activity and by potassium channel-mediated vasorelaxation), inhibition of thrombocyte aggregation or increasing cardiac myocontractility (by PGC-1α regulation) [56–60]. In addition, individuals with a single nucleotide polymorphism in the
One of the important stages in the pathophysiology of NAFLD is the inflammatory process, which is considered the “second hit” after steatosis and results in the development of NASH. One important effect of SIRT1 activation, which was discovered recently, is its anti-inflammatory effect. An important aspect of this effect is performed through regulation of NF-κB (a master transcription factor involved in the regulation of proinflammatory cytokines and a key part of NAFLD pathogenesis) [29]. Recent studies have shown that SIRT1 also deacetylates and suppresses the transcriptional activity of activator protein-1 (AP-1), leading to a down-regulation of cyclooxygenase-2 (COX-2) gene expression [62]. In addition, the expression of multiple proinflammatory mediators, such as intracellular adhesion molecule 1 (ICAM1), MCP1, RANTES (also known as CCL5), macrophage colony stimulating factor (M-CSF), granulocyte-macrophage CSF (GM-CSF), G-CSF, and transforming growth factor-β (TGF-β), is reduced by the SIRT1 activator resveratrol [63]. It has been demonstrated that SIRT1 activation protects cells from TNFα-induced insulin resistance. Thus, SIRT1 activity results in antiinflammatory effects through its regulation of multiple inflammatory pathways [64].
Another characteristic of SIRT1 activation, discovered in the last few years, is its effects on tumorigenesis. The antiproliferative, proapoptotic and tumor suppressing effects of SIRT1 activation have been elucidated by studies performed in rats [65,66]. Additionally, use of SIRT1 in cancer chemotherapy, based on its chemopreventive effects, has been considered [67]. Resveratrol has been shown to have anti-carcinogenic effects both
SIRT1 has also been shown to control the cell cycle, cell differentiation, cell proliferation and cell senescence by its regulation of the FOXO and p53 proteins [30].
Conclusions
A sedentary lifestyle and variations in dietary habits has significantly increased the frequency of metabolic syndrome and its hepatic component, NAFLD, and the number of patients with this condition continues to rise. The most important etiologic factor of NAFLD is insulin resistance. Currently, there is no validated evidence-based treatment algorithm, and patients are currently treated with recommendations for caloric limitation and increased physical activity.
In recent years, the positive effects of SIRT1 activation have been shown in the metabolic activities related to NAFLD pathophysiology. These activities include glycemic regulation, lipid homeostasis, insulin secretion and sensitivity, inflammatory processes, oxidative stress, endothelial dysfunction, mitochondrial biogenesis and β-oxidation, cellular senescence, autophagy/apoptosis and skeletal and heart muscle function. From these results, we believe that SIRT1 activation has potential as a therapeutic target to prevent both the progression and development of NAFLD. Recent studies have demonstrated the positive effects of SIRT1 activation on these metabolic activities after induction by resveratrol, a natural polyphenol. In addition, SIRT1 activators that are 1000 times more efficient than resveratrol are currently being developed and studied. Current policy requires that therapeutic efficiency and security profile evaluations in randomized controlled studies be performed for new pharmaceutical agents.
References
1. Ludwig J, Viggiano TR, McGill DB, Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease: Mayo Clin Proc, 1980; 55; 434-38, pmid: 7382552
2. Bellentani S, Scaglioni F, Marino M, Epidemiology of non-alcoholic fatty liver disease: Dig Dis, 2010; 28; 155-61, pmid: 20460905
3. Lewis JR, Mohanty SR, Nonalcoholic fatty liver disease: a review and update: Dig Dis Sci, 2010; 55; 560-78, pmid: 20101463
4. Day CP, James OF, Steatohepatitis: a tale of two “hits”?: Gastroenterology, 1998; 114; 842-45, pmid: 9547102
5. Jou J, Choi SS, Diehl AM, Mechanisms of disease progression in nonalcoholic fatty liver disease: Semin Liver Dis, 2008; 28; 370-79, pmid: 18956293
6. Torres DM, Harrison SA, Diagnosis and therapy of nonalcoholic steatohepatitis: Gastroenterology, 2008; 134; 1682-98, pmid: 18471547
7. Huang MA, Greenson JK, Chao C, One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study: Am J Gastroenterol, 2005; 100; 1072-81, pmid: 15842581
8. Klein S, Mittendorfer B, Eagon JC, Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease: Gastroenterology, 2006; 130; 1564-72, pmid: 16697719
9. Ratziu V, Giral P, Jacqueminet S, Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial: Gastroenterology, 2008; 135; 100-10, pmid: 18503774
10. Uygun A, Kadayifci A, Isik AT, Metformin in the treatment of patients with non-alcoholic steatohepatitis: Aliment Pharmacol Ther, 2004; 19; 537-44, pmid: 14987322
11. Yang T, Fu M, Pestell R, SIRT1 and endocrine signaling. Trends Endocrinol: Metab, 2006; 17; 186-91
12. Baur JA, Sinclair DA: Nat Rev Drug Discov, 2006; 5; 493-506, pmid: 16732220
13. Borra MT, Smith BC, Denu JM, Mechanism of human SIRT1 activation by resveratrol: J Biol Chem, 2005; 280; 17187-95, pmid: 15749705
14. Howitz KT, Bitterman KJ, Cohen HY, Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan: Nature, 2003; 425; 191-96, pmid: 12939617
15. Kaeberlein M, McDonagh T, Heltweg B, Substrate-specific activation of sirtuins by resveratrol: J Biol Chem, 2005; 280; 17038-45, pmid: 15684413
16. Cohen HY, Miller C, Bitterman KJ, Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase: Science, 2004; 305; 390-92, pmid: 15205477
17. Milne JC, Lambert PD, Schenk S, Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes: Nature, 2007; 450; 712-16, pmid: 18046409
18. Van den Berghe G, The role of the liver in metabolic homeostasis: implications for inborn errors of metabolism: J Inherit Metab Dis, 1991; 14; 407-20, pmid: 1749209
19. McCullough AJ, The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease: Clin Liver Dis, 2004; 8; 521-33, pmid: 15331061
20. Deng XQ, Chen LL, Li NX, The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats: Liver Int, 2007; 27; 708-15, pmid: 17498258
21. Chen LL, Deng XQ, Li NX, Effects of calorie restriction on SIRT1 expression in liver of nonalcoholic fatty liver disease: experiment with rats: Zhonghua Yi Xue Za Zhi, 2007; 87; 1434-37, pmid: 17785073
22. Purushotham A, Schug TT, Xu Q, Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation: Cell Metab, 2009; 9; 327-38, pmid: 19356714
23. Herranz D, Muñoz-Martin M, Cañamero M, Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer: Nat Commun, 2010; 1; 3, pmid: 20975665
24. Imai S, Armstrong CM, Kaeberlein M, Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase: Nature, 2000; 403; 795-800, pmid: 10693811
25. Landry J, Sutton A, Tafrov ST, The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases: Proc Natl Acad Sci USA, 2000; 97(11); 5807-11, pmid: 10811920
26. Smith JS, Brachmann CB, Celic I, A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family: Proc Natl Acad Sci USA, 2000; 97(12); 6658-63, pmid: 10841563
27. Luo J, Nikolaev AY, Imai S, Negative control of p53 by Sir2alpha promotes cell survival under stress: Cell, 2001; 107; 137-48, pmid: 11672522
28. Vaziri H, Dessain SK, Ng Eaton E, hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase: Cell, 2001; 107; 149-59, pmid: 11672523
29. Yeung F, Hoberg JE, Ramsey CS, Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase: EMBO J, 2004; 23; 2369-80, pmid: 15152190
30. Brunet A, Sweeney LB, Sturgill JF, Stresss-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase: Science, 2004; 303; 2011-15, pmid: 14976264
31. Motta MC, Divecha N, Lemieux M, Mammalian SIRT1 represses forkhead transcription factors: Cell, 2004; 116; 551-63, pmid: 14980222
32. Rodgers JT, Lerin C, Haas W, Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1: Nature, 2005; 434; 113-18, pmid: 15744310
33. Li X, Zhang S, Blander G, SIRT1 deacetylates and positively regulates the nuclear receptor LXR: Mol Cell, 2007; 28; 91-106, pmid: 17936707
34. Grimaldi B, Nakahata Y, Kaluzova M, Chromatin remodeling, metabolism and circadian clocks: The interplay of CLOCK and SIRT1: Int J Biochem Cell Biol, 2008; 41; 81-86, pmid: 18817890
35. Nakahata Y, Kaluzova M, Grimaldi B, The NAD+-dependent deacetylase SIRT1 modulates CLOCK-mediated chromatin remodeling and circadian control: Cell, 2008; 134; 329-40, pmid: 18662547
36. Liu Y, Dentin R, Chen D, A fasting inducible switch modulates gluconeogenesis via activator/coactivator Exchange: Nature, 2008; 456; 269-73, pmid: 18849969
37. Yamazaki Y, Usui I, Kanatani Y, Treatment with SRT1720, a SIRT1 Activator, Ameliorates Fatty Liver with Reduced Expression of Lipogenic Enzymes in MSG Mice: Am J Physiol Endocrinol Metab 9 1, 2009 [Epub ahead of print]
38. Costa Cdos S, Hammes TO, Rohden F, SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis: Obes Surg, 2010; 20; 633-39, pmid: 20033348
39. Bordone L, Motta MC, Picard F, Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells: PLoS Biol, 2006; 4; e31, pmid: 16366736
40. Moynihan KA, Grimm AA, Plueger MM, Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice: Cell Metab, 2005; 2; 105-17, pmid: 16098828
41. Lee JH, Song MY, Song EK, Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway: Diabetes, 2009; 58; 344-51, pmid: 19008341
42. Picard F, Kurtev M, Chung N, Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-g: Nature, 2004; 429; 771-76, pmid: 15175761
43. Banks AS, Kon N, Knight C, SirT1 gain of function increases energy efficiency and prevents diabetes in mice: Cell Metab, 2008; 8; 333-41, pmid: 18840364
44. Qiao L, Shao J, SIRT1 regulates adiponectin gene expression through Foxo1-C/EBPalpha transcriptional complex: J Biol Chem, 2006; 281; 39915-24, pmid: 17090532
45. Wang H, Qiang L, Farmer SR, Identification of a domain within peroxisome proliferator-activated receptor gamma regulating expression of a group of genes containing fibroblast growth factor 21 that are selectively repressed by SIRT1 in adipocytes: Mol Cell Biol, 2008; 28; 188-200, pmid: 17954559
46. Attie AD, Kastelein JP, Hayden MR, Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis: J Lipid Res, 2001; 42; 1717-26, pmid: 11714841
47. Oram JF, Lawn RM, ABCA1. The gatekeeper for eliminating excess tissue cholesterol: J Lipid Res, 2001; 42; 1173-79, pmid: 11483617
48. Gerhart-Hines Z, Rodgers JT, Bare O, Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha: Embo J, 2007; 26; 1913-23, pmid: 17347648
49. Mootha VK, Handschin C, Arlow D, Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle: Proc Natl Acad Sci USA, 2004; 101; 6570-75, pmid: 15100410
50. Patti ME, Butte AJ, Crunkhorn S, Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1: Proc Natl Acad Sci USA, 2003; 100; 8466-71, pmid: 12832613
51. Sun C, Zhang F, Ge X, SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B: Cell Metab, 2007; 6; 307-19, pmid: 17908559
52. Elchebly M, Payette P, Michaliszyn E, Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene: Science, 1999; 283; 1544-48, pmid: 10066179
53. Targher G, Arcaro G, Non-alcoholic fatty liver disease and increased risk of cardiovascular disease: Atherosclerosis, 2007; 191; 235-40, pmid: 16970951
54. Ekstedt M, Franzén LE, Mathiesen UL, Long-term follow-up of patients with NAFLD and elevated liver enzymes: Hepatology, 2006; 44; 865-73, pmid: 17006923
55. Targher G, Bertolini L, Padovani R, Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients: Diabetes Care, 2007; 30; 1212-18, pmid: 17277038
56. Das DK, Maulik N, Resveratrol in cardioprotection: a therapeutic promise of alternative medicine: Mol Interv, 2006; 6; 36-47, pmid: 16507749
57. Labinskyy N, Csiszar A, Veress G, Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen: Curr Med Chem, 2006; 13; 989-96, pmid: 16611080
58. Mattagajasingh I, Kim CS, Naqvi A, SIRT1 promotes endotheliumdependent vascular relaxation by activating endothelial nitric oxide synthase: Proc Natl Acad Sci USA, 2007; 104; 14855-60, pmid: 17785417
59. Novakovic A, Bukarica LG, Kanjuh V, Potassium channels-mediated vasorelaxation of rat aorta induced by resveratrol: Basic Clin Pharmacol Toxicol, 2006; 99; 360-64, pmid: 17076688
60. Stef G, Csiszar A, Lerea K, Resveratrol inhibits aggregation of platelets from high-risk cardiac patients with aspirin resistance: J Cardiovasc Pharmacol, 2006; 48; 1-5, pmid: 16954814
61. Kuningas M, Putters M, Westendorp RG, SIRT1 gene, agerelated diseases, and mortality: the Leiden 85-plus study: J Gerontol A Biol Sci Med Sci, 2007; 62; 960-65, pmid: 17895433
62. Zhang R, Chen HZ, Liu JJ, SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages: J Biol Chem, 2010; 285; 7097-110, pmid: 20042607
63. Leiro J, Arranz JA, Fraiz N, Effect of cis-resveratrol on genes involved in nuclear factor kappa B signaling: Int Immunopharmacol, 2005; 5; 393-406, pmid: 15652768
64. Yoshizaki T, Milne JC, Imamura T, SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes: Mol Cell Biol, 2009; 29; 1363-74, pmid: 19103747
65. Athar M, Back JH, Kopelovich L, Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms: Arch Biochem Biophys, 2009; 486; 95-102, pmid: 19514131
66. Boily B, He XH, Pearce B, SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol: Oncogene, 2009; 28; 2882-93, pmid: 19503100
67. Kundu JK, Surh YJ, Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives: Cancer Lett, 2008; 269; 243-46, pmid: 18550275
68. Wang RH, Zheng Y, Kim HS, Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis: Mol Cell, 2008; 32; 11-20, pmid: 18851829
69. Whyte L, Huang YY, Torres K, Molecular mechanisms of resveratrol action in lung cancer cells using dual protein and microarray analyses: Cancer Res, 2007; 67; 12007-17, pmid: 18089832
70. Elliott PJ, Jirousek M, Sirtuins: novel targets for metabolic disease: Curr Opin Investig Drugs, 2008; 9; 371-78
In Press
Clinical Research
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...Med Sci Monit In Press; DOI: 10.12659/MSM.951027
Clinical Research
Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...Med Sci Monit In Press; DOI: 10.12659/MSM.950516
Review article
Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.951283
Clinical Research
Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 AdultsMed Sci Monit In Press; DOI: 10.12659/MSM.950938
Most Viewed Current Articles
17 Jan 2024 : Review article 10,187,196
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,708,487
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,341,643
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 706,524
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387